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Abstract
Hyperglycemia and hypertension impair endothelial function in part through oxidative
stress-activated poly (ADP-ribose) polymerase 1 (PARP1). Biguanides and angiotensin II
receptor blockers (ARBs) such as metformin and telmisartan have a vascular protective
effect. We used cultured vascular endothelial cells (ECs), diabetic and hypertensive rodent
models, and AMPKα2-knockout mice to investigate whether metformin and telmisartan
have a beneficial effect on the endothelium via AMP-activated protein kinase (AMPK) phos-
phorylation of PARP1 and thus inhibition of PARP1 activity. The results showed that metfor-
min and telmisartan, but not glipizide and metoprolol, activated AMPK, which
phosphorylated PARP1 Ser-177 in cultured ECs and the vascular wall of rodent models.
Experiments using phosphorylated/de-phosphorylated PARP1 mutants show that AMPK
phosphorylation of PARP1 leads to decreased PARP1 activity and attenuated protein poly
(ADP-ribosyl)ation (PARylation), but increased endothelial nitric oxide synthase (eNOS)
activity and silent mating type information regulation 2 homolog 1 (SIRT1) expression.
Taken together, the data presented here suggest biguanides and ARBs have a beneficial
effect on the vasculature by the cascade of AMPK phosphorylation of PARP1 to inhibit
PARP1 activity and protein PARylation in ECs, thereby mitigating endothelial dysfunction.
Introduction
Endothelial function is impaired under pathophysiological conditions such as hyperglycemia
and hypertension, in part because of an imbalanced redox state. Induced by oxidative stress,
poly (ADP-ribose) polymerase 1 (PARP1) plays an important role in DNA repair and
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maintenance of genome stability. Although mild activation of PARP1 can be protective and
promote cell survival, excessive and sustained oxidative stress can cause overactivation of
PARP1, which escalates the oxidative stress and stimulates pro-inflammatory and necrotic
responses [1]. At the expense of NAD+, PARP1 synthesizes PAR for "PARylation" of itself and
other nuclear and cytoplasmic proteins, which depletes cellular NAD+ and ATP and activates
transcription factors such as NF-κB and AP-1 and inactivates SIRT1 deacetylase [2–5]. In addi-
tion to NF-κB activation, PARP1 exerts its pro-inflammatory effect by binding to the B-cell
lymphoma 6 (Bcl-6) intron 1 to suppress the expression of Bcl-6 protein [6].
Hyperglycemia, angiotensin II (Ang II), and oxidized low-density lipoprotein activate
PARP1 in vascular endothelial cells (ECs), with attendant increase in oxidative and inflamma-
tory stresses [7]. By contrast, inhibition of PARP1 in ECs protects against free radical-induced
cell death [8]. In vivo, mice with PARP1 ablation are spared from hyperglycemia-induced
endothelial dysfunction [9]. Furthermore, genetic ablation of PARP1 or administration of a
PARP1 inhibitor (e.g., PJ-34 and TIQ-A) to ApoE-/- mice, led to decreased atherosclerosis [10–
12], which suggests an atherogenic role for PARP1.
Biguanides (e.g., metformin) and sulfonylureas (e.g., glipizide) are first-line anti-diabetic
drugs. Ample evidence indicates that metformin reduces cardiovascular incidents, possibly by
improving vascular functions such as flow-mediated dilation (FMD) [13]. Data from clinical
studies suggest that patients taking metformin show improved FMD [14]. However, no evi-
dence suggests that glipizide improves EC functions or decreases vascular resistance. Regarding
anti-hypertensive drugs, both telmisartan, an antagonist of Ang II type 1 receptor (AT1R) and
metoprolol, a selective β1 receptor blocker, have a significant effect on lowering blood pressure.
Telmisartan decreases arterial stiffness and atherosclerosis by improving EC functions [15–17],
but metoprolol might not have this beneficial effect [18].
By phosphorylating substrates such as endothelial nitric oxide synthase (eNOS), peroxi-
some proliferator-activated receptor-γ (PPARγ) coactivator 1 (PGC-1), and sterol regula-
tory element-binding proteins (SREBPs), AMP-activated protein kinase (AMPK) increases
endothelial function via enhanced NO bioavailability and mitochondrial biogenesis and
decreased inflammatory and oxidative stresses [19]. Although we have previously shown
that PARP1 is a putative substrate of AMPK [20], the translational implication of this phos-
phorylation event in the broad context of vascular diseases and pharmacology has not been
explored. With newly developed anti-phospho-PARP1 antibody, we address these questions
with emphasis on improved endothelial functions by hyperglycemia and hypertension
treatment.
Materials and Methods
Materials
Antibodies against pan-AMPKα, phospho-AMPK Thr-172, eNOS, and phospho-eNOS Ser-
1177 were from Cell Signaling Technology (Beverly, MA); anti-AMPKα1 and anti-AMPKα2
antibodies were from Abcam (Cambridge, UK); anti-PARP1 and anti-PAR monoclonal anti-
bodies were from Trevigen (Gaithersburg, MD); anti-β-actin antibody was from Santa Cruz
Biotechnology (Santa Cruz, CA). Rabbit polyclonal anti-phospho-PARP1 Ser-177 antibody
was produced with the sequence “ELGFRPEY(pS)ASQ” by AbMax Biotechnology (Beijing,
China). Metformin, glipizide, telmisartan, metoprolol, atorvastatin, AICAR, Compound C and
PJ34 were from Sigma-Aldrich (St. Louis, MO). The PARP assay kit was from Trevigen (Gai-
thersburg, MD). NO detection kit was from Beyotime Biotechnology (Haimen, China).
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Cell culture, adenovirus, and EC infection and transfection
Human umbilical vein endothelial cells (HUVECs) were isolated from human umbilical cords.
With patients’ consensus, the cords were obtained from Department of Obstetrics and Gyne-
cology, the First Affiliated Hospital, Xi’an Jiaotong University. The protocol for the isolation of
endothelial cells was reviewed and approved by the Ethic Committee of Xi’an Jiaotong Univer-
sity Health Science Center. HUVECs were cultured in mediumM199 supplemented with 20%
fetal bovine serum (FBS), 1 ng/mL recombinant human fibroblast growth factor, 90 μg/mL
heparin, 20 mMHEPES (pH 7.4) and 100 U/mL penicillin-streptomycin. Bovine aortic endo-
thelial cells (BAECs) were a gift from Department of Physiology, Peking University. BAECs
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS
and antibiotics. Cells were maintained in a humidified 95% air, 5% CO2 incubator at 37°C. We
used a recombinant adenovirus expressing a constitutively-activated form of AMPKα2, hereaf-
ter called Ad-AMPK-CA. The parental adenoviral vector, called Ad-null, was used as an infec-
tion control. Confluent ECs were infected with recombinant adenoviruses at the indicated
multiplicity of infection (MOI) and incubated for 24 hr before experiments. ECs were trans-
fected with various DNA plasmids with the use of Lipofectamine 2000 RNAi Max (Invitrogen).
RT-qPCR analysis of mRNA
RNA was isolated from cultured cells or tissues by using TRIzol (Invitrogen). For mRNA quan-
tification, total RNA was reverse-transcribed (RT) by use of the iScript cDNA synthesis kit
(Invitrogen), followed by quantitative real-time PCR (qPCR) with SYBR Green (Promega) and
a 7500 realtime PCR system (Applied Biosystems). The relative level of mRNA was calculated
by the ΔΔ Ct method with GAPDH or other appropriate genes as an internal control.
Western blot analysis
Total proteins were extracted by use of RIPA buffer (6.5 mM Tris, pH 7.4, 15 mMNaCl, 1 mM
EDTA, 0.1% SDS, 0.25% sodium deoxycholate, 1% NP-40). Bicinchoninic Acid reagents
(Thermo Scientific) were used to measure the protein concentration. Equal amounts of pro-
teins were separated by SDS-PAGE and transferred to PVDF membranes. The blots were
immunoreacted with primary antibodies and secondary antibodies conjugated with horserad-
ish peroxidase. Protein bands were visualized by enhanced chemiluminescence detection and
the intensity was quantified by use of Scion Image software.
PARP1 activity measurement and NO generation detection
For the colorimetric PARP1 activity assay, EC nuclear extracts were incubated with histones
and PARP cocktail in a strip well format. The PARP1 activity was then assessed by incorpo-
ration with biotinylated poly(ADP-ribose), which was quantified by the reading the absorbance
at 450 nm. Serially diluted PARP-HSA (high specific activity) standards were used in parallel
to generate the standard curve for subsequent calculation. EC-derived NO was measured in
condition media by using Griess reagents following the standard protocol.
Animal experiments
The animal experiments were approved by the Institutional Animal Care and Use Committee
of Xi’an Jiaotong University (No. XJTULAC2014-208). All animals were housed in colony
cages (Animal Care Systems, Centennial, Colorado, USA) with a 12-hr light/12-hr dark cycle
ad libitum. We monitored the mouse and rat body weight, teeth, fur, and behavior on the daily
base. According to our close observation, there was no mortality during the experimental
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period. At the end of experiments, all animals were euthanized by CO2 and tissues were col-
lected afterwards for analyses. All treatments were by oral gavage. C57BL6 mice were pur-
chased from Experimental Animal Center of Xi’an Jiaotong University. Eight- to twelve-week-
old male C57BL6 mice were treated with metformin (200 mg/kg/day), glipizide (1.3 mg/kg/
day), telmisartan (10 mg/kg/day), metoprolol (30 mg/kg/day), or saline as a mock control for
up to 24 hr. AMPKα2-/- mice were a gift from Institute of Vascular Medicine, Peking Univer-
sity Third Hospital. AMPKα2-/- mice and their wild-type littermates (AMPKα2+/+) in a
C57BL6 background were treated with metformin (200 mg/kg/day) for 12 hr. Ten-week-old
db/db and age-matched db/m mice were purchased from the Model Animal Research Center
of Nanjing University. db/db mice were treated with metformin (200 mg/kg/day) or glipizide
(1.3 mg/kg/day) for 2 weeks. Fasting blood glucose was measured by use of the Accu-Check
Glucose Meter. Spontaneously hypertensive rats (SHRs) and Wistar-Kyoto (WKY) rats were
purchased from Vital River Laboratory Animal Technology (Beijing, China). Ten-week-old
male SHRs andWKY rats were fed standard chow diet and treated with telmisartan (10 mg/kg/
day) or metoprolol (30 mg/kg/day) for 8 weeks. Systolic arterial pressure was measured by tail-
cuff plethysmography.
Statistical Analysis
Significance of variability was determined by unpaired Student’s t test between two groups or
ANOVA for multiple comparisons. Data were expressed as mean±SD from at least 3 indepen-
dent experiments. p<0.05 was considered statistically significant.
Results
High glucose and Ang II decrease PARP1 Ser-177 phosphorylation in
ECs
Given that AMPK activity is inhibited under hyperglycemia and a high level of Ang II, both
known to augment oxidative stress in ECs [21,22], we first sought to test whether phosphoryla-
tion of PARP1 Ser-177 was also decreased under these conditions with the use of the newly
developed anti-phospho-PARP1. As expected, H2O2, high glucose and Ang II dose- and time-
dependently attenuated the phosphorylation of AMPKα Thr-172 and PARP1 Ser-177 in
HUVECs (Fig 1). Notably, the use of 30 mMmannitol did not decrease PARP1 and AMPK
phosphorylation as that of glucose did (S1 Fig). Further, although H2O2 at a lower concentra-
tion (1 μM) slightly induced AMPK and PARP1 phosphorylation (Fig 1A), these phosphoryla-
tion events were decreased at higher concentrations (e.g., 100 and 1000 μM).
Metformin and telmisartan increase PARP1 Ser-177 phosphorylation
Although metformin and glipizide are first-line drugs to treat type II diabetes, metformin, but
not glipizide, has an additional effect on vasculature [23]. Therefore, we examined whether
metformin and glipizide could induce PARP1 phosphorylation in HUVECs. Metformin treat-
ment indeed dose- and time-dependently increased the phosphorylation level of PARP1 Ser-
177 and AMPK Thr-172 in cultured HUVECs (Fig 2A and 2E). However, cells treated with gli-
pizide showed little increase in PARP1 and AMPK phosphorylation (Fig 2B and 2F). Regarding
anti-hypertensive medication, telmisartan improves EC functions, but metoprolol does not
seem to benefit the endothelium [17,18]. Similarly, telmisartan, but not metoprolol, induced
PARP1 and AMPK phosphorylation (Fig 2C, 2D, 2G and 2H). To recapitulate findings from
experiments with cultured HUVECs, we treated C57BL6 mice with metformin, glipizide, telmi-
sartan, and metoprolol. Compared with aortas of control mice receiving saline, aortas of mice
Metformin and Telmisartan Activates AMPK-PARP1
PLOSONE | DOI:10.1371/journal.pone.0151845 March 17, 2016 4 / 16
with metformin or telmisartan treatment showed increased PARP1 Ser-177 and AMPK Thr-
172 phosphorylation (Fig 3A and 3C). However, glipizide and metoprolol administration did
not significantly increase the phosphorylation of PARP1 or AMPK (Fig 3B and 3D). Together,
results presented in Figs 1–3 suggest that phosphorylation of PARP1 Ser-177 agreed with
AMPK activity in ECs under pathophysiological conditions (i.e., elevated oxidative stress) or
with pharmacological interventions (i.e., metformin and telmisartan).
PARP1 Ser-177 Phosphorylation is AMPK-dependent
Because PARP1 Ser-177 is a putative AMPK phosphorylation site [20], we investigated
whether PARP1 phosphorylation in HUVECs is AMPK-dependent. HUVECs were infected
with Ad-AMPK-CA (a constitutively active form for AMPKα2) at different multiplicity of
infection (MOI) and control cells were infected with Ad-null at 50 MOI. Ectopic expression of
Fig 1. H2O2, high glucose, and Ang II inhibit phosphorylation of AMPK Thr-172 and PARP1 Ser-177 in HUVECs.Western blot analysis of AMPK Thr-
172 and PARP1 Ser-177 in HUVECs treated with concentrations of H2O2 (A), glucose (B), and Ang II (C) for 4 hr. (D-F) treated with H2O2 (100 μM), glucose
(30 mM), or Ang II (100 nM) for the indicated times. Data are mean±SD ratio of phospho-PARP1 Ser-177 to total PARP1 and phospho-AMPK Thr-172 to total
AMPK from 3 independent experiments. *p<0.05 compared to controls.
doi:10.1371/journal.pone.0151845.g001
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a constitutively active form of AMPKα2 increased the phosphorylation of AMPK Thr-172 and
that of PARP1 Ser-177 (Fig 4A). Furthermore, activation of endogenous AMPK by 5-aminoi-
midazole-4-carboxamide ribonucleotide (AICAR) increased phosphorylation of PARP1 and
AMPK in HUVECs under high glucose and Ang II (Fig 4B and 4C). In a complementary
experiment (Fig 4D), the increased phosphorylation of AMPK and PARP1 in response to met-
formin was attenuated by pretreatment with the AMPK inhibitor Compound C.
To explore whether AMPK is involved in the PARP1 phosphorylation in vivo, we assessed
metformin-induced PARP1 phosphorylation in aortas from AMPKα2-/- mice and their wild-
type littermates (i.e., AMPKα2+/+). Consistent with results from in vitro experiments, the phos-
phorylation of PARP1 Ser-177 was lower in metformin-administered AMPKα2-/- than
AMPKα2+/+ mice (Fig 4E).
PARP1 Ser-177 phosphorylation affects endothelial function
Next, we examined the role of AMPK phosphorylation of PARP1 Ser-177 in modulating
PARP1 activity and related EC function. Because both high glucose and Ang II can activate
Fig 2. Metformin and telmisartan enhance AMPK and PARP1 phosphorylation in HUVECs.Western blot analysis of AMPK Thr-172 and PARP1 Ser-
177 phosphorylation in HUVECs treated with concentrations of metformin (A), glipizide (B), telmisartan (C), and metoprolol (D) for 4 hr or (E-H) metformin (5
mM), glipizide (500 nM), telmisartan (5 μM), and metoprolol (500 μM) for the indicated times. Data are mean±SD ratio of phospho-PARP1 to total PARP1 and
phospho-AMPK to total AMPK from 3 independent experiments. *p<0.05 compared to controls.
doi:10.1371/journal.pone.0151845.g002
Metformin and Telmisartan Activates AMPK-PARP1
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PARP1 and cause endothelial dysfunction [24,25], we cultured HUVECs under high glucose or
Ang II with or without AICAR to examine whether activation of AMPK can inhibit PARP1
activation and consequent PARylation. With 30 mM glucose or Ang II treatment, the protein
level of PAR was increased in HUVECs as compared with respective controls (Fig 5A and 5B).
Co-incubation with AICAR significantly reduced the high glucose- or Ang II-induced protein
Fig 3. Metformin and telmisartan induce AMPK and PARP1 phosphorylation in mouse aortas. Twelve week-old male C57BL6 mice were administered
(A) metformin (200 mg/kg body weight), (B) glipizide (1.3 mg/kg body weight), (C) telmisartan (10 mg/kg body weight), or (D) metoprolol (30 mg/kg body
weight) for the indicated times. Control mice received 0.5 ml saline. Western blot analysis of AMPK and PARP1 phosphorylation in aortic extracts from 2 mice
pooled. Data are mean ± SD ratio of phospho-PARP1 to total PARP1 and phospho-AMPK to total AMPK (n = 8 mice per group). *p<0.05 compared to
controls.
doi:10.1371/journal.pone.0151845.g003
Fig 4. AMPK phosphorylates PARP1 Ser-177 in vitro and in vivo.Western blot analysis of protein levels in cell lysates and aortic extracts. (A) HUVECs
were infected with Ad-AMPK-CA at 50 or 100 multiplicities of infection (MOI) or Ad-null virus at 50 MOI for 24 hr. (B,C) HUVECs were pre-treated with or
without AICAR (1 mM) for 30 min before the addition of glucose (30 mM) or Ang II (100 nM) at the indicated concentrations for 4 hr. (D) HUVECs were pre-
treated with or without Compound C (15 μM) for 30 min before metformin (5 mM) for 4 hr. (E) AMPKα2+/+ and AMPKα2-/- mice were orally administered with
or without metformin (200 mg/kg body weight) and aortas were collected after 12 hr. Data are mean±SD ratio of phospho-PARP1 to total PARP1 and
phospho-AMPK to total AMPK from at least 3 experiments in A-D and n = 8 animals in E. *p<0.05 compared with controls.
doi:10.1371/journal.pone.0151845.g004
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PARylation (Fig 5A and 5B). We then compared the effect of metformin versus glipizide and
telmisartan versus metoprolol on protein PARylation. Metformin reduced PARylation, and gli-
pizide had little effect on HUVECs under 30 mM glucose (Fig 5C). Similarly, telmisartan, but
not metoprolol, decreased Ang II-increased PARylation (Fig 5D). These results are consistent
with PARP1 activity assay (S2 Fig).
To confirm further whether AMPK phosphorylation of PARP1 Ser-177 inhibited PARP1
activity and PARylation, we transfected BAECs with plasmids encoding the wild-type, de-
phospho-mimetic S177A PARP1, or phospho-mimetic S177D PARP1. High glucose or Ang II
increased protein PARylation in BAECs transfected with wild-type PARP1, and overexpression
of PARP1 S177A increased PARylation both at the basal level and with glucose or Ang II
Fig 5. AMPK phosphorylation of PARP1 Ser-177 regulates EC function. (A-F) Western blot analysis of protein PAR in EC lysates. (A, B) HUVECs were
pre-treated with or without AICAR for 4 hr before the addition of glucose (30 mM) (A) or Ang II (100 nM) (B) and incubated for another 24 hr. (C) HUVECs
were treated with or without metformin or glipizide for 6 hr, then incubated with or without 30 mM glucose for 24 hr. (D) HUVECs were treated with or without
telmisartan or metoprolol for 6 hr, then incubated with or without 100 nM Ang II for 24 hr. (E, F) BAECs were transfected with flag-tagged wild-type (WT),
S177A, or S177D PARP1 plasmids for 24 hr, then incubated with 30 mM glucose (E) or 100 nM Ang II (F) for 6 hr. (G) BAECs were transfected with S177A or
S177D PARP1 plasmid. RT-PCR analysis of mRNA level of eNOS, SIRT1, KLF4, MCP-1, and VCAM-1. (H, I) BAECs were transfected with S177A or S177D
PARP1 or WT PARP1 treated with or without PJ-34 (3 μM for 6 hr). (H) Western blot analysis and quantification of protein levels. (I) Measurement of PARP1
activity in nuclear extracts of BAECs and NO level in the cultured medium. Data are mean±SD from at least 3 experiments. *p<0.05 compared with controls.
doi:10.1371/journal.pone.0151845.g005
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stimulation (Fig 5E and 5F). In contrast, protein PARylation was lower with PARP1 S177D
than S177A or wild-type transfection at the basal level and under glucose or Ang II stimulation.
Given the strong inhibition of protein PARylation by PARP1 S177D, we further examined its
effect on the expression of genes critical to BAEC function. As expected, the mRNA level of
eNOS, SIRT1 and Krüppel-like factor 4 (KLF4) was higher and that of monocyte chemoattrac-
tant protein-1 (MCP-1) and vascular cell adhesion molecule-1 (VCAM-1) was lower in BAECs
with PARP1 S177D than S177A overexpression (Fig 5G). We also compared p-eNOS Ser-1177
and SIRT1 protein level in BAECs transfected with PARP1 S177A or S177D mutants. In a par-
allel experiment, wild-type PARP1-transfected BAECs were treated with PJ-34, a PARP1 phar-
macological inhibitor. The effect of PARP1 S177D overexpression was similar with PJ-34
treatment, both of which decreased PARP1 activity and protein PARylation but increased
eNOS Ser-1177 phosphorylation, SIRT1 expression level, and NO bioavailability (Fig 5H and
5I). Thus, AMPK phosphorylation of PARP1 Ser-177 inhibits PARP1 activity and hence
improves endothelial function.
Metformin and telmisartan activate the AMPK-PARP1 cascade in
diabetic and hypertensive animal models
To provide in vivo evidence for the AMPK-PARP1 cascade and its downstream function, we
used diabetic and hypertensive rodent models and compared the drug effect of metformin ver-
sus glipizide and that of telmisartan versus metoprolol in the long-term (i.e., 2 and 8 weeks). At
the basal level, namely untreated groups, db/db mouse and SHR aortas showed lower phos-
phorylation of AMPKα, PARP1, and eNOS and higher protein PARylation than db/m mouse
andWKY rat aortas, respectively (left panels, Fig 6A, 6B, 6D and 6E). Consistent with previous
reports, metformin and glipizide had similar glucose-lowering effect in db/db mice (S3 Fig). As
well, telmisartan and metoprolol decreased blood pressure in SHR to the comparable level (S4
Fig). However, metformin but not glipizide, increased the phosphorylation of AMPKα,
PARP1, and eNOS and decreased protein PARylation in db/db mouse aortas (right panel, Fig
6A and 6B). Telmisartan, but not metoprolol, increased the phosphorylation of AMPKα,
PARP1, and eNOS and decreased protein PARylation in SHR aortas (right panel, Fig 6D and
6E). To associate the activation of AMPK-PARP1 with vascular function in various models, we
assessed the expression of genes affecting EC function positively (e.g., eNOS, SIRT1, KLF4) or
negatively (e.g., ICAM-1, VCAM-1). The mRNA levels of eNOS, SIRT1 and KLF4 were lower
and those of ICAM-1 and VCAM-1 higher in db/db mouse and SHR aortas than db/m mouse
andWKY rat controls, respectively. Metformin but not glipizide improved EC functions in dia-
betic db/db mouse aortas, as indicated by decreased expression of ICAM-1 and VCAM-1 and
increased expression of eNOS, SIRT1, and KLF4 (Fig 6C). A similar vascular beneficial effect
was found in aortas of SHRs receiving telmisartan but not metoprolol (Fig 6F).
Discussion
Herein, we demonstrated for the first time that AMPK phosphorylation of PARP1 Ser-177 in
vivo, which contributes to the endothelial protection in the context of anti-hypertensive and
anti-diabetic drugs. Although vasculature is directly benefited from the blood pressure and glu-
cose lowering effect, additional therapeutic efficacy of some, but not all, of these drugs may
build on the endothelial protection because of this AMPK-dependent PARP1 inhibition. Thus,
the major translational implication of this finding is that the vascular protection of metformin
and telmisartan occurs in part through activation of the AMPK-PARP1 cascade.
Clinical studies such as the UK Prospective Diabetes Study (UKPDS) have underscored the
vasoprotective effect of metformin. In contrast, patients receiving sulfonylurea (e.g., glipizide)
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did not show a similar extent of cardiovascular protection despite glycemic control [23,26,27].
Vasoprotection with metformin is mediated in part, if not predominantly, by improved EC
function [28]. At the molecular level, metformin increased AMPK activity in adipose tissue
from diabetic patients, which was not observed with sulfonylurea treatment [29]. Additionally,
metformin improves endothelial function in obese mice by inhibition of ER stress through
AMPK/PPARδ pathway [30]. Hyperglycemia associated with diabetes mellitus is known to
impair endothelial function, as manifested by PARP1 activation and resulting oxidative and
inflammatory stresses [24]. Given our findings that metformin can induce AMPK phosphory-
lation of PARP1 Ser-177 and in turn inhibit PARP1 activation, the AMPK-PARP1 axis may be
an important mechanism underlying the vasoprotective effect of metformin. Phenformin,
Fig 6. Metformin and telmisartan activate the AMPK-PARP1 cascade in aortic vessel wall of rodents under hyperglycemia and hypertension. db/m
and db/db mice were treated with metformin (200 mg/kg/day) or glipizide (1.3 mg/kg/day) for 2 weeks. SHR andWKY rats were treated with telmisartan (10
mg/kg/day) or metoprolol (30 mg/kg/day) for 8 weeks. (A, D) Western blot analysis of protein levels in aortic extracts from various animal groups were
analyzed by western blotting with various antibodies as indicated. (B, E) Scatter plots of ratio of phospho-PARP1 to total PARP1, phospho-AMPKα to total
AMPKα, and PAR to β-actin for each aortic specimen. (C, F) RT-PCR analysis of mRNA level of eNOS, SIRT1, KLF4, ICAM-1, and VCAM-1 in rodent aortas.
*p<0.05 compared with controls.
doi:10.1371/journal.pone.0151845.g006
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another biguanide class of drug, also activates the AMPK-PARP1 axis in HUVECs (S5 Fig).
Metformin is also used to treat polycystic ovary syndrome that is often associated with endo-
thelial dysfunction [31,32]. AMPK phosphorylation of PARP1 Ser-177 may also contribute to
the improved EC function in PCOS patients receiving metformin [33].
Although endothelial dysfunction is prevalent in hypertensive patients, the protective effect
of anti-hypertensive drugs on the endothelium is less clear than that of biguanides. In the 2014
evidence-based guideline for management of hypertension in adults, the Eighth Joint National
Committee (JNC 8) recommended ARBs as a first-line treatment, with β-blockers as later-line
alternatives in part because of the higher rate of cardiovascular events associated with β-block-
ers as compared with ARBs [34]. Several small-scale clinical studies indicated that telmisartan
improved FMD in patients with essential hypertension or metabolic syndrome [15,35,36]. As
well, the ARBs losartan and irbesartan were found superior to atenolol (a selective β1 blocker)
in improving the structure and EC function of resistant arteries [37,38]. Likewise, telmisartan,
but not metoprolol, restored eNOS activity and ameliorated oxidative stress in diabetic rats
[39,40]. Others showed that telmisartan activated PPARγ in macrophages and ECs [17,41,42],
and we demonstrated that telmisartan, but not metoprolol, activated the AMPK-PARP1 axis,
which provides additional evidence for the cardiovascular protective effect of telmisartan. This
finding is consistent with a report by Sharma et al showing that metoprolol did not change
AMPK activity or phosphorylation of acetyl-CoA carboxylase, a canonical substrate of AMPK
[43].
Mechanistically, AMPK phosphorylation of PARP1 Ser-177 resembled the pharmacological
inhibition of PARP1 by PJ-34 (Fig 5), which reduced PARP1 activity. Given that PARP1 posi-
tively regulates NF-κB, p38, and c-Jun N-terminal kinase (JNK) [3,44], AMPK phosphoryla-
tion of PARP1 would suppress these pro-oxidative and pro-inflammatory pathways. We found
the expression of eNOS, SIRT1, and KLF4 increased and that of MCP-1 and VCAM-1
decreased (Fig 5G), which indicates improved EC function.
Besides AMPK, several kinases have been shown to regulate PARP1. However, these phos-
phorylation events increase, rather than decrease, PARP1 activity. Extracellular signal-regu-
lated kinase (ERK) can bind to PARP1 and phosphorylate Ser-372 and Thr-373 to enhance
PARP1 activity [45,46]. In the context of EC biology, inhibition of ERK can decrease disturbed
flow-induced PARP1 activity [47]. As well, JNK can interact with and phosphorylate PARP1 to
increase PARP1 activity [48]. With the robust induction of PARP1 by oxidative stress, ERK
and/or JNK activation under hyperglycemia and hypertension may contribute to increased
PARP1 activity. In contrast, metformin and telmisartan decreased PARP1 activity via the
AMPK-PARP1 cascade, as shown in the current study. Therefore, AMPK phosphorylation of
PARP1 would counteract other phosphorylation events activating PARP1.
Noticeably, statins (known to activate AMPK) [49] and other ARBs may also activate this
beneficial pathway because atorvastatin and losartan increased PARP1 phosphorylation in
ECs. On the other hand, other sulfonylurea drugs and β-blockers lack this beneficial effect
(S6 and S7 Figs). While our study provides molecular basis of additional vascular beneficial
effect of metformin and telmisartan in hyperglycemic or hypertensive patients, these results
by no means challenge the clinical use of metoprolol and glipizide. Rather, given that meto-
prolol has profound effect in treating patients with heart failure, ischemic heart disease, or
arrhythmia, combinatory use of drugs such as telmisartan or statins may provide additional
vascular protection. Likewise, the combined use of glipizide, metformin, and statins may
show pleiotropic effect in the vessels of patient with diabetes through activation of the
AMPK-PARP1 axis.
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S1 Fig. High glucose decreased AMPK phosphorylation of PARP1 Ser-177 in HUVECs.
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S2 Fig. Metformin or Telmisartan, but not Glipizide and Metoprolol, reduced PARP1
activity induced by high glucose or Ang II.
(PDF)
S3 Fig. Metformin or glipizide lowered blood glucose in db/db mice.
(PDF)
S4 Fig. Telmisartan or Metoprolol decreased blood pressure in SHR.
(PDF)
S5 Fig. Phenformin increased AMPK phosphorylation of PARP1 Ser-177 in HUVECs com-
pared to glimepiride.
(PDF)
S6 Fig. Losartan enhanced AMPK phosphorylation of PARP1 Ser-177 in HUVECs com-
pared to atenolol.
(PDF)
S7 Fig. Atorvastatin augmented AMPK phosphorylation of PARP1 Ser-177 in HUVECs.
(PDF)
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